Warning letter
Frontida BioPharm Inc: warning letter of Aug 15, 2016
FDA warning letter 473486 · Philadelphia District Office
Key facts
| Reference number | 473486 |
|---|---|
| Company | Frontida BioPharm Inc |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Aug 15, 2016 |
| Posted date | Aug 22, 2016 |
| Issuing office | Philadelphia District Office |
| Product type | Drugs |
| CFR sections cited | 211.22(a) |
| Inspection city | Philadelphia |
| Inspection ZIP | 19111 |
| Inspection start date | Jun 15, 2015 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: